- H80 -

Duchenne Mucular Dystrophy Working towards a cure 15th Annual Jeffrey Steele Concert Saturday October 15 2022 22nd Annual FORE Duchenne Monday May 12 2025 25th Annual Dining Away Duchenne Monday September 15 2025 The Story of the Foundation to Eradicate Duchenne Media Release Rockville MD The EMA approved AGAMREE vamorolone for Duchenne muscular dystrophy DMD ages 4 years and older on 18 December 2023. The US FDA previously approved AGAMREE for DMD 26 October 2023. This makes AGAMREE the first pharmacological intervention poised to receive full approval for DMD populations in both the US and EU. AGAMREE was developed utilizing an innovative public and private participation model with central governments nonprofit foundations and commercial stage research and development organizations working in coordination to advance the development program from discovery through clinical trials all the way to drug approval.